IGM Biosciences goes public

Mountain View, California-based IGM Biosciences Inc, a biotech firm focused on developing engineered IgM antibodies for therapeutic use, has raised about $175 million for its IPO of nearly 11 million shares at $16 per share. The stock began trading September 18, 2019 on the NASDAQ under the ticker symbol "IGMS." The lead underwriters are Jefferies, Piper Jaffray, Stifel and Guggenheim Securities. IGM's pre-IPO backers include Redmile Group, Janus Henderson Investors and Vivo Capital.

DealsNorth AmericaUSBriefs